Metabolic Acetate Therapy Improves Phenotype in the Tremor Rat Model of Canavan Disease
Abstract
Genetic mutations that severely diminish the activity of aspartoacylase (ASPA) result in the fatal brain dysmyelinating disorder, Canavan disease. There is no effective treatment. ASPA produces free acetate from the concentrated brain metabolite, N-acetylaspartate (NAA). Because acetyl coenzyme A is a key building block for lipid synthesis, we postulated that the inability to catabolize NAA leads to a brain acetate deficiency during a critical period of CNS development, impairing myelination and possibly other aspects of brain development. We tested the hypothesis that acetate supplementation during postnatal myelination would ameliorate the severe phenotype associated with ASPA deficiency using the tremor rat model of Canavan disease. Glyceryltriacetate (GTA) was administered orally to tremor rats starting 7 days after birth, and was continued in food and water after weaning. Motor function, myelin lipids, and brain vacuolation were analyzed in GTA-treated and untreated tremor rats. Significant improvements were observed in motor performance and myelin galactocerebroside content in tremor rats treated with GTA. Further, brain vacuolation was modestly reduced, and these reductions were positively correlated with improved motor performance.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 13, 2010
- Accession Number
- ADA520790
Entities
People
- Aryan M. Namboodiria
- Chikkathur N. Madhavarao
- John M Denu
- John R. Moffett
- Kristen Hamilton
- Neil E. Grunberg
- Peethambaran Arun
- Prasanth S. Ariyannur
- Steven Mog
- William A. Gahl
- William C. Hallows
- Yair Anikster
Organizations
- Uniformed Services University of the Health Sciences